[go: up one dir, main page]

PE20160124A1 - Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr - Google Patents

Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr

Info

Publication number
PE20160124A1
PE20160124A1 PE2016000013A PE2016000013A PE20160124A1 PE 20160124 A1 PE20160124 A1 PE 20160124A1 PE 2016000013 A PE2016000013 A PE 2016000013A PE 2016000013 A PE2016000013 A PE 2016000013A PE 20160124 A1 PE20160124 A1 PE 20160124A1
Authority
PE
Peru
Prior art keywords
dichloropyridin
indazol
vinyl
ethanol
compound
Prior art date
Application number
PE2016000013A
Other languages
English (en)
Inventor
Daohong Chen
Genshi Zhao
Hong-Yu Li
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20160124A1 publication Critical patent/PE20160124A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona compuestos, caracterizado porque es (E)-2-4(4-(2(5-(1-(3,5-dicloropiridin-4-il) etoxi)-1H-indazol-3-il) vinil)-1H-pirazol-1-il) etanol, o el compuesto (I), o una sal del mismo farmaceuticamente aceptable, util en el tratamiento de cancer
PE2016000013A 2009-05-07 2010-05-04 Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr PE20160124A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17629009P 2009-05-07 2009-05-07
US30141610P 2010-02-04 2010-02-04

Publications (1)

Publication Number Publication Date
PE20160124A1 true PE20160124A1 (es) 2016-02-24

Family

ID=42238704

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001877A PE20120812A1 (es) 2009-05-07 2010-05-04 Compuestos vinil indazolilo
PE2016000013A PE20160124A1 (es) 2009-05-07 2010-05-04 Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001877A PE20120812A1 (es) 2009-05-07 2010-05-04 Compuestos vinil indazolilo

Country Status (34)

Country Link
US (1) US8268869B2 (es)
EP (1) EP2427449B1 (es)
JP (1) JP5555314B2 (es)
KR (1) KR101373910B1 (es)
CN (1) CN102421769B (es)
AR (1) AR078411A1 (es)
AU (1) AU2010246114B2 (es)
BR (1) BRPI1013748A2 (es)
CA (1) CA2760535C (es)
CL (1) CL2011002781A1 (es)
CO (1) CO6450624A2 (es)
CR (1) CR20110580A (es)
DK (1) DK2427449T3 (es)
EA (1) EA018149B1 (es)
EC (1) ECSP11011441A (es)
ES (1) ES2408117T3 (es)
HN (1) HN2011002809A (es)
HR (1) HRP20130323T1 (es)
IL (1) IL216004A (es)
JO (1) JO2860B1 (es)
MA (1) MA33244B1 (es)
ME (1) ME01462B (es)
MX (1) MX2011011342A (es)
MY (1) MY160390A (es)
NZ (1) NZ595553A (es)
PE (2) PE20120812A1 (es)
PL (1) PL2427449T3 (es)
PT (1) PT2427449E (es)
RS (1) RS52795B (es)
SG (1) SG175909A1 (es)
SI (1) SI2427449T1 (es)
TW (1) TWI382982B (es)
UA (1) UA104756C2 (es)
WO (1) WO2010129509A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2702305T3 (es) 2012-03-08 2019-02-28 Astellas Pharma Inc Nuevo producto de fusión de FGFR3
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014151734A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014172644A2 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN103819396B (zh) * 2014-02-26 2016-06-15 四川大学 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016105517A1 (en) 2014-12-23 2016-06-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN105906621A (zh) * 2015-04-06 2016-08-31 四川百利药业有限责任公司 用作fgfr抑制剂的乙醇类化合物
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
WO2017024968A1 (zh) * 2015-08-07 2017-02-16 南京明德新药研发股份有限公司 作为fgfr和vegfr抑制剂的乙烯基化合物
JP6549311B2 (ja) 2015-08-20 2019-07-24 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． インドール誘導体、その調製方法および医薬におけるその使用
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (en) 2019-10-14 2022-08-24 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4056558A4 (en) * 2019-11-06 2023-12-27 Jinan University INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USES THEREOF
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4069695A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4186894B1 (en) * 2020-08-11 2024-12-04 Henan Medinno Pharmaceutical Technology Co., Ltd. Fgfr inhibitor compound and use thereof
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN116554148B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种乙烯基吲唑类氘代fgfr抑制剂药物及用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
AU9327501A (en) 2000-09-11 2002-03-26 Chiron Corp Quinolinone derivatives
WO2003033472A1 (en) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
CN1656079A (zh) * 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
EA200601985A1 (ru) 2004-05-26 2007-04-27 Пфайзер Лимитед Новые производные индазола и индолона и их применение в качестве фармацевтических средств
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
JP2009531274A (ja) * 2005-12-07 2009-09-03 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド キナーゼ阻害性ピロロピリジン化合物
CN101594862B (zh) 2006-12-20 2015-11-25 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代吲唑衍生物
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
PE20090326A1 (es) 2007-06-05 2009-04-04 Schering Corp Compuestos heterociclos como inhibidores de erk
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
JP2011511005A (ja) * 2008-02-04 2011-04-07 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド ２−アミノピリジン系キナーゼ阻害薬

Also Published As

Publication number Publication date
NZ595553A (en) 2013-05-31
CO6450624A2 (es) 2012-05-31
CA2760535C (en) 2014-01-14
CR20110580A (es) 2012-01-06
PE20120812A1 (es) 2012-07-08
MY160390A (en) 2017-03-15
PT2427449E (pt) 2013-05-06
US8268869B2 (en) 2012-09-18
IL216004A (en) 2014-01-30
EP2427449A1 (en) 2012-03-14
HK1163665A1 (en) 2012-09-14
MA33244B1 (fr) 2012-05-02
JP5555314B2 (ja) 2014-07-23
CA2760535A1 (en) 2010-11-11
AU2010246114B2 (en) 2012-12-06
US20100286209A1 (en) 2010-11-11
KR101373910B1 (ko) 2014-03-12
CN102421769B (zh) 2014-04-02
TW201105652A (en) 2011-02-16
EP2427449B1 (en) 2013-04-03
HN2011002809A (es) 2013-07-22
EA018149B1 (ru) 2013-05-30
ES2408117T3 (es) 2013-06-18
SI2427449T1 (sl) 2013-05-31
MX2011011342A (es) 2011-11-18
UA104756C2 (uk) 2014-03-11
BRPI1013748A2 (pt) 2016-04-05
JP2012526126A (ja) 2012-10-25
RS52795B (sr) 2013-10-31
CN102421769A (zh) 2012-04-18
HRP20130323T1 (en) 2013-05-31
SG175909A1 (en) 2011-12-29
EA201171367A1 (ru) 2012-04-30
PL2427449T3 (pl) 2013-08-30
KR20120004511A (ko) 2012-01-12
ME01462B (me) 2014-04-20
ECSP11011441A (es) 2011-12-30
WO2010129509A1 (en) 2010-11-11
IL216004A0 (en) 2012-01-31
TWI382982B (zh) 2013-01-21
CL2011002781A1 (es) 2012-05-25
AU2010246114A1 (en) 2011-11-03
DK2427449T3 (da) 2013-04-22
JO2860B1 (en) 2015-03-15
AR078411A1 (es) 2011-11-09

Similar Documents

Publication Publication Date Title
PE20160124A1 (es) Compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol como inhibidor de fgfr
JO3062B1 (ar) R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR089818A1 (es) Inhibidor de la quinasa que regula la señal de la apoptosis
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
ZA201100026B (en) 4-(pyridin-4-yl)-1h-(1,3,5)triazin-2-one derivatives as gsk3-beta inhibitors for the treatment of neurodegenerative diseases
PE20130239A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
NZ594163A (en) Pyranose derivatives of pestcidal 1,2,4-triazoles
UY31811A (es) Azoles sustituidos como fungicidas
PE20190343A1 (es) Combinaciones de compuestos activos
CL2009000923A1 (es) Compuestos derivados de 1-(aminoacetil)-n-(1-cicloalquil)pirrolidina-2-carboxamida sustituidas; composicion farmaceutica; utiles para tratar la hepatitis c.
TN2015000521A1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
NZ599513A (en) Compounds for the treatment of dyslipidemia and related diseases
CO6382122A2 (es) Compuestos útiles para inhibir chk1
MX346186B (es) Inhibidores de proteina cinasas.
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
CU24020B1 (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6
AR067813A1 (es) Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53
EA201000613A1 (ru) Тризамещенные пиперидины
AR087700A1 (es) Inhibidores de aldh-2 en el tratamiento de adicciones
TH132151A (th) ((r)-(e)-2-(4-(2-(5-(1-(3,5-ไดคลอโรไพริดิน-4-อิล)เอทธอกซี)-1h-อินดาซอล-3-อิล)ไวนิล)-1h-ไพราซอล-1-อิล)เอทธานอลเชิงผลึก
CY1117146T1 (el) Κρυσταλλικη (r)-(ε)-2-(4-(2-(5-(1-(3,5-διχλωροπυριδινο-4-υλ)αιθοξυ)-1 η-ινδαζολο-3-υλ)βινυλο)-1 η-πυραζολο-1-υλ)αιθανολη και η χρηση της ως αναστολεα του fgfr
ECSP099383A (es) Derivado piperidínico utilizado para tratar enfermedades mediadas por el receptor 5 de quimiocina
IN2013MU02719A (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed